Aide Biotech: AmoyDx® PIK3CA Gene Mutation Detection Kit Approved for Market Launch in Japan

People’s Financial News, March 23 — Aide Biological (300685) announced on March 23 that its self-developed AmoyDx® PIK3CA Gene Mutation Detection Kit has recently been approved for market launch by Japan’s Ministry of Health, Labour and Welfare. The product is intended to detect PIK3CA gene mutations in patients with ovarian clear cell carcinoma and serve as a companion diagnostic for Resorcyclic acid.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin